Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
- 1 March 2011
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (5) , 683-689
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast CancerJournal of Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast CancerJournal of Clinical Oncology, 2008
- Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialBreast Cancer Research and Treatment, 2008
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic AcidClinical Cancer Research, 2007
- Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of lifeEuropean Journal of Cancer, 2007
- Effect of early menopause on bone mineral density and fracturesMenopause, 2007
- Skeletal Complications of Breast Cancer TherapiesClinical Cancer Research, 2006
- Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual StatusJournal of Clinical Oncology, 2006
- Chemotherapy-Induced Ovarian FailureDrug Safety, 2005